On Friday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was -4.55% drop from the session before settling in for the closing price of $5.5. A 52-week range for TSHA has been $1.05 – $6.02.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -63.99%. When this article was written, the company’s average yearly earnings per share was at -0.86%. With a float of $223.27 million, this company’s outstanding shares have now reached $273.92 million.
Taysha Gene Therapies Inc (TSHA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 18.49%, while institutional ownership is 89.58%. The most recent insider transaction that took place on Dec 01 ’25, was worth 1,172,812. In this transaction President and Head of R&D of this company sold 260,047 shares at a rate of $4.51, taking the stock ownership to the 1,006,439 shares. Before that another transaction happened on Nov 28 ’25, when Company’s President and Head of R&D sold 110,125 for $4.75, making the entire transaction worth $523,094. This insider now owns 1,006,439 shares in total.
Taysha Gene Therapies Inc (TSHA) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.07 earnings per share (EPS) during the time that was better than consensus figure (set at -0.08) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.28% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 227.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
As of the previous 9 days, the stock’s Stochastic %D was 16.82%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 76.88%, which indicates a significant increase from 10.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.26 in the past 14 days, which was lower than the 0.29 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.88, while its 200-day Moving Average is $3.24. Nevertheless, the first resistance level for the watch stands at $5.47 in the near term. At $5.68, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.84. If the price goes on to break the first support level at $5.10, it is likely to go to the next support level at $4.94. Now, if the price goes above the second support level, the third support stands at $4.73.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are 273,919K outstanding shares of the company, which has a market capitalization of 1.44 billion. As of now, sales total 8,330 K while income totals -89,300 K. Its latest quarter income was 1,990 K while its last quarter net income were -26,880 K.
